Complementary pre-screening strategies to uncover hidden prodromal and mild Alzheimer's disease: Results from the MOPEAD project.

Autor:	Boada M; Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades - Universitat Internacional de Catalunya, Barcelona, Spain.; Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Barcelona, Spain., Rodrigo A; GMV SECURE E SOLUTIONS, Valencia, Spain., Jessen F; Department of Psychiatry, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.; Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Faculty of Medicine and University Hospital Cologne, Cologne, Germany., Wimblad B; Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna, Sweden.; Theme Aging, Karolinska Univ Hospital, Stockholm, Sweden., Kramberger MG; Department of Neurology, University Medical Center Ljubljana and Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia., Visser PJ; Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.; Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands., Simó R; Institut de Recerca Vall d'Hebron, Universitat Autònoma de Barcelona (VHIR-UAB), Barcelona, Spain.; CIBER de Diabetes y Enfermedades Metabólicas Asociadas. Instituto de Salud Carlos III, Spain., Rodríguez-Gomez O; Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades - Universitat Internacional de Catalunya, Barcelona, Spain., Ciudin A; Institut de Recerca Vall d'Hebron, Universitat Autònoma de Barcelona (VHIR-UAB), Barcelona, Spain.; CIBER de Diabetes y Enfermedades Metabólicas Asociadas. Instituto de Salud Carlos III, Spain., Georges J; Alzheimer Europe, Luxembourg., Dumas A; ASDM Consulting, Brussels, Belgium., Maguire P; European Institute of Women's Health, Dublin, Ireland., Krivec D; Zdruzenje Spomincica, Ljubljana, Slovenia., Wimo A; Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna, Sweden., Valero S; Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades - Universitat Internacional de Catalunya, Barcelona, Spain.; Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Barcelona, Spain., Alegret M; Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades - Universitat Internacional de Catalunya, Barcelona, Spain.; Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Barcelona, Spain., Jamilis L; GMV SECURE E SOLUTIONS, Valencia, Spain., Zwan M; Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands., Sannemann L; Department of Psychiatry, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany., Arrufat J; EAP Sarrià-Vallvidrera-Les Planes, Barcelona, Spain., Stomrud E; Clinical Memory Research Unit, Lund University, Malmö, Sweden.; Emmaboda Health Centre, Region Kalmar County, Emmaboda, Sweden., Johansson G; Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna, Sweden., Shering C; AstraZeneca, Waltham, Massachusetts, USA., Glaysher B; Modus Research and Innovation Limited, Dundee, Scotland., Stewart N; Modus Research and Innovation Limited, Dundee, Scotland., Belger M; Eli Lilly and Company (Lilly UK), Surrey, UK., Iradier F; Eli Lilly and Company, Spain., Campo L; Eli Lilly and Company, Firenze, Italy.
Jazyk:	angličtina
Zdroj:	Alzheimer's & dementia : the journal of the Alzheimer's Association [Alzheimers Dement] 2022 Jun; Vol. 18 (6), pp. 1119-1127. Date of Electronic Publication: 2021 Jul 26.
DOI:	10.1002/alz.12441
Abstrakt:	Introduction: The Models of Patient Engagement for Alzheimer's Disease (MOPEAD) project was conceived to explore innovative complementary strategies to uncover hidden prodromal and mild Alzheimer's disease (AD) dementia cases and to raise awareness both in the general public and among health professionals about the importance of early diagnosis. Methods: Four different strategies or RUNs were used: (a) a web-based (WB) prescreening tool, (2) an open house initiative (OHI), (3) a primary care-based protocol for early detection of cognitive decline (PC), and (4) a tertiary care-based pre-screening at diabetologist clinics (DC). Results: A total of 1129 patients at high risk of having prodromal AD or dementia were identified of 2847 pre-screened individuals (39.7%). The corresponding proportion for the different initiatives were 36.8% (WB), 35.6% (OHI), 44.4% (PC), and 58.3% (DC). Conclusion: These four complementary pre-screening strategies were useful for identifying individuals at high risk of having prodromal or mild AD. (© 2021 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu